ISM8207 (QPCTL inhibitor)
Insilico Medicine (with Fosun): company profile
Phase 1 registry
Since , the date of the source that reports this phase.
Summary
ISM8207 is a QPCTL inhibitor from Insilico Medicine (with Fosun). The source describes it as small molecule. It is being developed for advanced solid tumors and relapsed or refractory B-cell lymphoma. ClinicalTrials.gov lists it at Phase 1 (recruiting) under NCT06445517. The AI role named in the source is molecule design. Registry records: NCT06445517, Phase 1, recruiting, updated Jul 24, 2026. About the company: Pharma.AI, an end-to-end generative AI platform covering target discovery (PandaOmics), molecule generation (Chemistry42) and clinical prediction, backed by lab automation. The latest dated source is from Jul 24, 2026.
Built only from the sources listed on this page.
Facts
- Company
- Insilico Medicine (with Fosun)
- Indication
- Advanced solid tumors and relapsed or refractory B-cell lymphoma
- Therapeutic area
- Oncology
- Modality
- Small molecule
- AI role
- Molecule design
- Phase in the source
- Phase 1, as of Jul 24, 2026
- Phase source
- Registry
- Board column
- Phase 1
AI evidence
AI source: Paper
“ISM8207 is an inhibitor of glutaminyl-peptide cyclotransferase and was designed using an AI-powered small molecule generation platform called Chemistry42.”
Source: paper (opens in new tab) The program page (opens in new tab) carries the AI wording.
Trial records
- NCT06445517 on ClinicalTrials.gov (opens in new tab) Phase 1 Recruiting Updated
Milestone timeline
-
NCT06445517 first posted on ClinicalTrials.gov
-
ClinicalTrials.gov record: Phase 1
-
NCT06445517 record updated
Phase 1, Recruiting
About Insilico Medicine
Pharma.AI, an end-to-end generative AI platform covering target discovery (PandaOmics), molecule generation (Chemistry42) and clinical prediction, backed by lab automation.
Spot an error? Tell me and I'll fix it.